Skip to content

Autologous Micro-fragmented Adipose Tissue in the Treatment of Minor Amputations of Diabetic Foot

Local Inoculation of Autologous Micro-fragmented Adipose Tissue in the Treatment of Minor Amputations of Diabetic Foot: A Randomized Controlled Trial

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03276312
Enrollment
112
Registered
2017-09-08
Start date
2015-04-30
Completion date
2018-03-31
Last updated
2018-06-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Diabetic Foot

Keywords

Lipogems, Adipose-derived Mesenchymal Stem Cells, Lipofilling, Diabetic foot

Brief summary

This is a randomized controlled monocentric study on 114 diabetic patients with the aim of evaluating the efficacy of the lipofilling with Lipogems® system in diabetic patients that are candidates for a minor amputation in the foot. In particular, it will be evaluated whether the lipofilling will be able to shorten the healing times and to reduce the number of major amputations, with consequent positive impact on the quality of life. Patients will be randomized to the treatment group with Lipogems® (local injection of autologous micro-fractured adipose tissue) or to the control group, thus, treatment according to standard clinical practice.

Detailed description

Primary objective of this study is the evaluation of the time of the healing of the lesions resulting from minor amputations (digital or forefoot) treated with Lipogems® technique. Secondary objectives are: 1) assessment of the safety of the lipofilling; 2) evaluation of the intensity of pain (VAS); 3) assessment of the skin tropism; 4) calculation of the relapse rate (defined as the occurrence of local infections, dehiscence and suffering of skin flaps that lead to a revision of the amputation stump or amputation at a higher level); 5) evaluation of the time of hospitalization and quality of life (QoL).

Interventions

DEVICELipogems

Lipogems® is an innovative system that, starting from minimum quantities of autologous lipoaspirate, provides, with a minimal manipulation, a micro-fragmented and non-expanded adipose tissue product

Sponsors

University of Modena and Reggio Emilia
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Intervention model description

Randomized controlled study

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

1. Patients with diabetes (diabetes mellitus type 1 and type 2) of both sexes over the age of 18 years. 2. Presence of irreversible gangrene digital or localized at forefoot (with X-ray of the foot negative or positive for osteolytic lesions at phalanges and/or metatarsus). 3. Patients with vascular problems absent or resolved (evaluated with Eco Color Doppler and ABI (Ankle Brachial Index, that calculates the ratio of the systolic pressure measured at the ankle and the systolic pressure in the arm, both measured in supine position using wave continue Doppler. If assessable, it has to be greater than/equal to 0.7) and pressure index finger/arm TBI (Toe Brachial Index, if assessable, it has to be greater than/equal to 0.6) and/or by the determination of the transcutaneous oxygen pressure (TcPO2 that needs to be equal to or greater than 30mmHg).

Exclusion criteria

1. Oncological treatments ongoing or previous (past 5 years) and/or neoplastic lesions 2. Patient under steroid therapy 3. Active vascular issues

Design outcomes

Primary

MeasureTime frameDescription
Healing time6 monthsHealing time after the minor amputation intended as the complete healing of the amputation stump

Secondary

MeasureTime frameDescription
Incidence of relapse6 monthsRelapse is intended as revision of the amputation stump or amputation at a higher level
Pain assessed using the Visual Analogue Scale (VAS) for pain6 monthsPain will be assessed using the VAS pain scale
Safety: All types of adverse events will be collected6 monthsAll types of adverse events will be collected
Total time of immobility6 monthsImmobility of the patient will be assessed counting the number of bed rest days
Quality of Life using the Short Form 36 (SF-36) questionnaire6 monthsAssessment of the quality of life (QoL) before surgery and during all the subsequent follow up visits using the SF-36 questionnaire
Total time of hospitalization6 monthsHospitalization of the patient will be assessed counting the number of days in hospital

Countries

Italy

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Mar 2, 2026